Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's $2.2 billion takeover offer "significantly undervalues" the company, but left the door open for talks on a possible deal.Endo, which is seeking to expand its men's healthcare products business, made an unsolicited offer for Auxilium last week, prompting the company to adopt a "poison pill" takeover defense.Auxilium said it maintained the right to engage in discussions with Endo, while Endo said it was willing to work with Auxilium on a deal.A deal would probably scupper Auxilium's agreement to purchase Canadian eye-drug maker QLT Inc. Endo, whose men's healthcare products include testosterone replacement therapy Aveed, has said it is only interested in Auxilium.
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. Shares of AUXL fell by 0.77% or $-0.24/share to $30.90. In the past year, the shares have traded as low as $16.36 and as high as $32.89. On average, 1566920 shares of AUXL exchange hands on a given day and today's volume is recorded at 647363.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLT fell by 2.09% or $-0.12/share to $5.62. In the past year, the shares have traded as low as $4.33 and as high as $7.90. On average, 5316 shares of QLT.TO exchange hands on a given day and today's volume is recorded at 600.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLTI fell by 0.96% or $-0.05/share to $5.15. In the past year, the shares have traded as low as $4.16 and as high as $7.10. On average, 205030 shares of QLTI exchange hands on a given day and today's volume is recorded at 16688.
Source
